CA-GUPSHUP
20.4.2022 07:02:12 CEST | Business Wire | Press release
Gupshup , a global leader in conversational engagement, announced today the acquisition of AskSid , a leading Conversational AI provider to top ecommerce and retail companies around the world. AskSid’s full-stack AI solution including the Retail AI brain, strengthens Gupshup’s customer experience (CX) offerings and will help make the entire shopping journey - across pre-purchase, purchase and post-purchase phases - fully conversational.
Headquartered in Bengaluru, AskSid is helping many global brands like AkzoNobel, Danone, Wolford, Akris and Himalaya Wellness deliver impactful shopping experiences to customers through AI-powered conversations, driving faster sales. The tech startup has operations in 25+ countries and supports over 100 languages. By automating 92% of support conversations with a self-service model, AskSid customers have reported an average 25% reduction in operational expenditure, while boosting order conversion rate by 30%.
“Conversational commerce is about to transform shopping, both online and offline. Gupshup is building the most comprehensive conversational commerce solution and AskSid’s deep-domain AI offering will help us bring even more advanced capabilities to ecommerce and retail businesses worldwide,” said Beerud Sheth, Co-founder and CEO, Gupshup. “We welcome the AskSid team onboard and look forward to collaborating with major brands across the world to enable next-gen shopping experiences.”
Per a recent report by McKinsey , ecommerce could grow up to 5x faster compared to pre-pandemic times. “This presents a huge opportunity for Retail and ecommerce brands - but only if they are able to provide expert guidance anytime, anywhere to their consumers, which is exactly what AskSid delivers,” said Sanjoy Roy, Co-founder and CEO, AskSid. “Together with Gupshup, we will help businesses drive richer conversational experiences.”
“We are very happy to join forces with Gupshup and look forward to helping more brands personalize their shopping experiences at scale,” said Dinesh Sharma, Co-founder and CTO, AskSid.
AskSid’s angel investors include well-known technology leaders Rajan Anandan (ex-Google), Krishnakumar Natarajan (ex-Mindtree), Parthasarathy NS (ex-Mindtree) and Radha R (ex-Microsoft and Mindtree). The AI startup is also backed by Techstars (first institutional investor in AskSid), a global seed accelerator that mentors some of the world’s most successful startups.
"AskSid’s retail-specific models help global retail brands deliver impactful shopping experiences to their consumers. I am impressed with AskSid's powerful AI capabilities and their ability to acquire global brands so readily," said Vijay Tirathrai, Managing Director at Techstars. “The merger with Gupshup is the next logical step and a great strategic fit as their deep vertical AI expertise in retail now gets augmented by Gupshup on a global scale in CPaaS and CX, delivering immense value to enterprise customers."
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005659/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 14:01:00 CEST | Press release
DCX introduces groundbreaking new safety standard protecting critical AI infrastructure by monitoring and keeping the entire coolant loop Continuous monitoring of eight coolant parameters and automatic dosing keep hall-scale liquid-cooling loops in specification between service visits Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 14:00:00 CEST | Press release
Company’s Third Largest Shareholder Expects Update on Increased Transparency, Strategic Review of Xerox Financial Services Business Unit, and Continued DeleveragingSTARTEEPO Chairman František Bostl to Address Xerox Investment at Skytop Conference in London STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executin
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release
Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release
More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom